Biodesix Q3 EPS $(1.16) Beats $(1.45) Estimate, Sales $21.768M Beat $20.974M Estimate

Author: Benzinga Newsdesk | November 03, 2025 04:42pm
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.45) by 20 percent. This is a 17.14 percent increase over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $21.768 million which beat the analyst consensus estimate of $20.974 million by 3.79 percent. This is a 19.93 percent increase over sales of $18.151 million the same period last year.

Posted In: BDSX